AbbVie ’s ABT-494 demonstrates positive outcome in Phase II trial for Crohn's disease

AbbVie has reported positive results from the Phase II CELEST clinical trial of upadacitinib (ABT-494) for the treatment of patients with Crohn's disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news